

# PhD evaluation — Alkayyali

---

SDC

29 January 2015

Compiled Thursday 29<sup>th</sup> January, 2015, 19:36  
from: /home/bendix/sdc/eval/PhD/alkayyali/eval.tex

Bendix Carstensen   Steno Diabetes Center, Gentofte, Denmark  
& Department of Biostatistics, University of Copenhagen  
bxc@steno.dk  
<http://BendixCarstensen.com>

# Contents

<b>1</b>	<b>Evaluation of Alkayyali's papers</b>	<b>1</b>
1.1	Statement concerning PhD-thesis . . . . .	1
1.2	Specific comments . . . . .	1

# 1 Evaluation of Alkayyali's papers

The evaluation of the thesis is based on 4 papers, and a more detailed background for the following statement can be found in the subsequent section.

## 1.1 Statement concerning PhD-thesis

The focus of the 4 papers presented (one published, 3 manuscripts) is assessment of the effect of genetic variants on mortality and complications in diabetes patients, and has therefore required accessing genotypical as well as phenotypical information from several studies. The genotypical information acquisition seems well described (however I have very limited knowledge in this field), whereas the phenotypical (clinical) information is less consistently reported between studies.

In general the epidemiological analyses appear weak and not well explained in the papers, in particular the second paper ("Shared genetic...") has flaws in the explanation of methods as well as inconsistent event counts (12% extra deaths appear).

Moreover the fourth paper has severe methodological omissions that possibly invalidates the conclusions even though this question could have been resolved quite easily (with unknown result, though). Also it seems odd to make the last two papers (on the DOLCHE study) separate, the famine analysis could easily have been included in the first paper — it is basically a single extra variable (although pointing at different loci).

In conclusion I find it difficult to recommend to the University of Lund to pass a PhD with two major flawed manuscripts out of 4.

## 1.2 Specific comments

There are 4 papers, where I have the following comments, on which I have built my statement above:

Common variant in the *HMGA2* gene ...

This is an analysis of genetic risk factors for nephropathy. The studies entering the analyses are not uniformly described which makes it difficult to evaluate the internal validity of the study. Although there seem to be follow-up data available, an over-simplified logistic regression of the end status of participants' nephropathy status have been used. The reason for this is not entirely clear.

*KCNJ11*/E23K polymorphism increases ...

This is an analysis of (in particular) CVD mortality in 3+1+6 cohort studies focusing on genes identified through analyses of the first 3 studies. The studies are not described homogeneously, and it is not indicated when follow-up started for any of them. Despite this it is in the methods section stated that data were treated as left truncated and right censored. This seems to indicate that time since baseline is not the underlying timescale (in which case there would be no left truncation), but it is not stated which is the underlying timescale used.

In table 1 is given  $276+200=476$  CVD deaths in the two first studies, which is also found in table 1 under analysis with RS5219 as covariate, but for the other three SNPs there are suddenly *more* than 476 CVD deaths.

The total number of events (deaths) is not mentioned in the results section at all, only the number of persons in the studies. The total number of deaths cannot be checked because they are not given in table 1.

In conclusion, it is unclear what survival analysis were made, unclear how many CVD deaths there were available, and it appears the the author is not aware the the number of deaths is the determinant of the precision of the results.

This paper does not meet scientific standards for reporting survival studies.

Shared genetic susceptibility for micro- and macro-vascular ...

This is a prevalence study of complications in 2203 Ukrainian DM patients. It is well reported and transparently analyzed.

It is a bit odd that prevalence is termed “risk” in the statistics section. Of slightly more concern is that in table 1 the DN+ / DN– classification only seem to have 1888 patients and not 2203 as the others, that is 315 patients less, quite a number since there are only 347 with DN+.

It is also not argued why analysis of macro-vascular complications are adjusted for age at DM, while analyses of micro-vascular complications are adjusted for duration of DM. And in particular why none of them are adjusted for age at investigation.

The limitations of a cross-sectional study where some exposures may contribute to mortality and thus removal of patients from the study population is not mentioned.

Famine exposure and genetic susceptibility to ...

This is essentially a replica of the previous study, but including famine exposure, defined as birth prior to 1950. Since data are collected in 2011–?? — a very short period, the famine exposure is almost the same as age over 62 (approximately). Incidentally the information about the *timing* of the data collection is absent in this paper even though large parts of the material and methods sections are identical to those in the previous.

The potential massive confounding by age which is so closely associated to the famine measure is not discussed at all in the paper. It is stated that clinical characteristics did not differ after adjustment for age, yet none of the main analyses are adjusted for age; only for age at DM onset and duration of DM. Thus it must be strongly suspected that results relating to famine are mere age-effects. Which is a pity since it would have been easy to adjust for age at examination (interview).